Combination therapy with copanlisib and venetoclax in B-cell non-Hodgkin’s lymphoma

SAKK 66/18

Coordinating investigator

PD Dr. med.
Anastasios
Stathis
Istituto Oncologico della Svizzera Italiana (IOSI)
+41 91 811 89 31

Non-Hodgkin's lymphomas (NHL) are among the ten most frequent cancers occurring in adults. Although treatment of NHL has improved significantly in recent decades, many patients still cannot be cured. That also applies to people suffering from follicular lymphoma (FL) or mantle cell lymphoma (MCL), two subtypes of B-cell NHL.

Trial SAKK 66/18 is investigating a new type of therapy for patients with B-cell NHL who have suffered a recurrence or proven to be therapy-resistant following standard treatments. The combination of copanlisib (Aliqopa™) and venetoclax (Venclyxto™) is examined, as it is thought that this may produce synergistic effects.

The medicines are administered in 4-week (28-day) cycles. In each cycle, the patients receive an intravenous copanlisib infusion on days 1, 8 and 15. As of day 2 of the trial, patients additionally take the prescribed dose of venetoclax daily. Treatment is continued for a maximum of 12 cycles. A maximum of 38 patients will be included in the trial.

All trials